Printed from Voxsanity (voxsanity.com.au) — NCT07504588 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
NCT07504588
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with high-grade serous or endometrioid epithelial ovarian cancer (including fallopian tube, ovarian, or primary peritoneal cancer), confirmed by tissue testing.
- People whose cancer is considered "platinum-sensitive," meaning the cancer did not come back or get worse until at least 6 months after their last platinum-based chemotherapy.
- People whose cancer got worse while they were taking a PARP inhibitor as a first-line maintenance treatment for advanced ovarian cancer, with no other cancer treatments received between that point and joining the trial.
- People whose cancer has a BRCA1 or BRCA2 gene mutation (in the blood or tumour), or whose cancer tested positive for homologous recombination deficiency (a type of DNA repair problem) — (confirm with trial site).
- People whose cancer can be measured or tracked using standard imaging criteria.
- People who have had brain metastases (cancer that spread to the brain) that were previously treated, as long as a brain scan taken at least 4 weeks after treatment shows the cancer there is stable and not growing, and steroids are no longer needed.
- People aged 18 or older.
- People with a general health and activity level rated at 0, 1, or 2 on the ECOG scale, meaning they are able to carry out some or all daily activities (confirm with trial site).
- People who are not currently pregnant and not breastfeeding.
- People whose blood counts and organ function meet the required levels, including: white blood cell count, platelet count, haemoglobin, kidney function, liver function, and urine protein levels within the ranges required by the trial.
- People with a known liver condition called Gilbert's disease may still be eligible if their bilirubin level is within a specific range (confirm with trial site).
- People with a history of heart disease or prior treatment with heart-affecting therapies, provided a heart function assessment places them in New York Heart Association class 2B or better (confirm with trial site).
- People who have recovered from most side effects of prior cancer treatment, with certain exceptions allowed: grade 2 or lower nerve problems, any level of hair loss, well-controlled high blood pressure, thyroid conditions controlled with medication, and a history of blood clots currently managed with blood thinners.
- People who have had major surgery must have fully recovered from any complications before starting the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have received any topoisomerase-I inhibiting medicines at any point previously.
- People who have taken an experimental (investigational) medicine within 4 weeks before joining the trial.
- People currently receiving any other cancer treatment, including chemotherapy, targeted therapy, biological therapy, immunotherapy, or hormone therapy for this cancer.
- People whose last dose of a PARP inhibitor was less than 3 weeks before joining the trial.
- People with an active infection that requires intravenous (IV) antibiotics.
- People with a wound, ulcer, or bone fracture that has not healed.
- People with an abdominal abscess, certain abdominal or pelvic fistulas, a hole in the bowel (gastrointestinal perforation), a bowel blockage, or who need a drainage tube through the nose or stomach.
- People who have had significant bleeding within 28 days before joining the trial.
- People with uncontrolled high blood pressure (systolic 160 mmHg or higher, or diastolic 100 mmHg or higher).
- People who still have side effects from previous cancer treatment rated above grade 1 in severity, unless they fall under the specific exceptions listed above.
- People who have had major surgery within 3 weeks before joining the trial.
- People currently taking strong medicines that affect the UGT1A1 enzyme (confirm with trial site for specific medicines).
- People with a known allergic reaction to the study drug or to medicines with a similar chemical or biological make-up.
- People whose cancer has undergone additional surgery (secondary or cytoreductive surgery) after starting the trial and before disease progression is confirmed are not permitted to continue under these conditions.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
10 September 2026
Est. completion
12 April 2029
Primary endpoints
Progression-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.